ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Acute gouty arthritis meeting the American College of Rheumatology (ACR) criteria for acute arthritis of primary gout;
- Onset of pain from an acute gouty arthritis attack within 48 hours prior to Screening/Baseline (Visit 1);
- A rating of moderate, severe, or extreme (2, 3, or 4, respectively) on the Patient's assessment of pain intensity in the index joint (5-point scale:0-4) at Screening/Baseline.
- Diagnosis of any other type of arthritis including those types suspected of being
infectious in origin in the index joint or presence of any acute trauma of the index
joint. Patients with osteoarthritis will be included as long as it is mild or moderate
(according to investigator's criteria) and it does not affect the index joint;
- Acute polyarticular gout involving greater than 4 joints or chronic gout.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Glendale, Arizona
- Mesa, Arizona
- Paradise Valley, Arizona
- Peoria, Arizona
- Roseville, California
- San Diego, California
- San Luis Obispo, California
- Longmont, Colorado
- Northglenn, Colorado
- DeLand, Florida
- Gainesville, Florida
- Tampa, Florida
- Atlanta, Georgia
- Dunwoody, Georgia
- Rockford, Illinois
- Lexington, Kentucky
- Mt. Sterling, Kentucky
- Shreveport, Louisiana
- Shreveport, Louisiana
- Wheaton, Maryland
- Lansing, Michigan
- Chaska, Minnesota
- Columbia, Missouri
- Columbus, Missouri
- St. Louis, Missouri
- Omaha, Nebraska
- Mineola, New York
- Statesville, North Carolina
- Lyndhurst, Ohio
- Willoughby Hills, Ohio
- Duncansville, Pennsylvania
- Havertown, Pennsylvania
- Nashville, Tennessee
- New Tazewell, Tennessee
- Beaumont, Texas
- Beaumont, Texas
- Bryan, Texas
- Dallas, Texas
- San Antonio, Texas
- San Antonio, Texas
- Tyler, Texas
- Richmond, Virginia
- Milwaukee, Wisconsin
- Langley, British Columbia
- Winnipeg, Manitoba
- St. John's, Newfoundland and Labrador
- Corunna, Ontario
- Sarnia, Ontario
- Toronto, Ontario
- Windsor, Ontario
- Saskatoon, Saskatchewan
- Quebec,
- Barranquilla, Atlantico
- Barranquilla, Atlantico
- Bucaramanga, Santander
- Cartago,
- Heredia,
- Suwon-si, Kyeongki-do
- Daegu,
- Mexico, D.f.
- Mexico, DF
- Guadalajara, Jalisco
- Lima,
- Lima,
- Lima,
- Lipa City, Batangas
- Las Piñas City,
- Manila,
- Manila,
- Manila,
- Quezon City,
- Moscow,
- Petrozavodsk,
- St. Petersburg,
- St. Petersburg,
- Sevilla,
- Hualien,
- Taichung,
- Taipei,
- Phayathai, Bangkok
- Khon Kaen,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Celebrex In Acute Gouty Arthritis Study | |||
Official Title ICMJE | A Phase 3, Randomized, Double-Blind, Multicenter, Active-Controlled Trial To Evaluate The Efficacy And Safety Of Celecoxib (Celebrex®) And Indomethacin In The Treatment Of Moderate To Severe Acute Gouty Arthritis | |||
Brief Summary | This is a multicenter, double-blind, double-dummy, randomized, active-controlled study that will include an 8-day treatment period followed by a 1-week follow-up period in patients experiencing symptoms of an acute exacerbation of gouty arthritis. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 3 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Investigator, Outcomes Assessor) Primary Purpose: Treatment | |||
Condition ICMJE | Arthritis, Gouty | |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Fravel MA, Ernst ME. Management of gout in the older adult. Am J Geriatr Pharmacother. 2011 Oct;9(5):271-85. doi: 10.1016/j.amjopharm.2011.07.004. Epub 2011 Aug 17. Review. | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 402 | |||
Original Enrollment ICMJE | 400 | |||
Actual Study Completion Date ICMJE | December 2009 | |||
Actual Primary Completion Date | December 2009 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Canada, Colombia, Costa Rica, Korea, Republic of, Mexico, Peru, Philippines, Russian Federation, Spain, Taiwan, Thailand, United States | |||
Removed Location Countries | Italy, United Kingdom | |||
Administrative Information | ||||
NCT Number ICMJE | NCT00549549 | |||
Other Study ID Numbers ICMJE | A3191219 | |||
Has Data Monitoring Committee | Yes | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Director Clinical Trial Disclosure Group, Pfizer | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | January 2011 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |